Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30634119 | 0.92 | NPC1 (0.51) | NPC1RAB9ASMN1; SMN2MCHR1HRH3 | |
| SCHEMBL30306680 | 0.92 | NPC1 (0.52) | NPC1RAB9ASMN1; SMN2MCHR1HRH3 | |
| SCHEMBL26764251 | 0.92 | NPC1 (0.52) | NPC1RAB9ASMN1; SMN2MCHR1HRH3 | |
| SCHEMBL26764300 | 0.92 | NPC1 (0.51) | NPC1RAB9ASMN1; SMN2MCHR1HRH3 | |
| SCHEMBL26633906 | 0.92 | NPC1 (0.51) | NPC1RAB9ASMN1; SMN2MCHR1HRH3 | |
| SCHEMBL26764290 | 0.92 | NPC1 (0.50) | NPC1RAB9ASMN1; SMN2MCHR1HRH3 | |
| SCHEMBL26633710 | 0.91 | NPC1 (0.56) | NPC1RAB9ASMN1; SMN2DRD3MCHR1 | |
| SCHEMBL30306711 | 0.90 | GAA (0.51) | NPC1RAB9ASMN1; SMN2MCHR1HRH3 | |
| SCHEMBL26764296 | 0.90 | ALDH1A1 (0.51) | NPC1RAB9ASMN1; SMN2MCHR1HRH3 | |
| SCHEMBL26764294 | 0.90 | NPC1 (0.48) | NPC1RAB9ASMN1; SMN2MCHR1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115843295-B | NAMPT modulators | 赛特凯恩蒂克公司 | 2025-04-15 | — | — | CN | disclosed |
| US-20230348369-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230348369-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230348369-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-11-02 | — | — | US | disclosed |
| CN-115843295-A | NAMPT modulators | 赛特凯恩蒂克公司 | 2023-03-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348369-A1 | NAMPT MODULATORS | NAMPT, NNT, NAPRT | NPC1 128/4885RAB9A 814/4885SMN1; SMN2 610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.